Alzheimer Disease as a Clinical-Biological Construct—An International Workin...

lion

[size=8.4813pt]the recently revised Alzheimer Association (AA) criteria for
[size=8.4813pt]Alzheimer disease (AD)
[size=8.4813pt]propose that AD be defined on
[size=8.4813pt]biological evidence only. The diagnosis of AD can be pro
[size=8.4813pt]vided to cognitively normal people with evidence of core 1 AD bio
[size=8.4813pt]markers encompassing cerebrospinal fluid (CSF) amyloid β and tau
[size=8.4813pt]ratios and plasma phosphorylated tau (p-tau) 217 validated against
[size=8.4813pt]amyloid positron emission tomography (PET), even though these
[size=8.4813pt]new criteria do not recommend testing for these biomarkers in
[size=8.4813pt]cognitively normal individuals. This raises the question of the role
[size=8.4813pt]and influence of biomarkers in the diagnostic workup.